抗生物質の世界市場：洞察、競合情勢、市場予測：2030年

世界の抗生物質の市場規模は、2023年に442億米ドルとなりました。同市場は、2024年から2030年までの予測期間中に4.91%でのCAGRで拡大し、2030年には589億米ドルに達すると予測されています。抗生物質市場は、感染症の流行増加、中低所得国における抗生物質の消費増加、先進的な治療法を開発するための研究開発の増加、感染症にかかりやすい高齢者人口の増加などの要因によって成長が促進されており、さらに予測期間中（2024年～2030年）に抗生物質市場の顕著な収益成長をもたらすと予想されます。

抗生物質市場の注目すべき促進要因の中でも、抗生物質による治療が必要とされる感染症の流行が増加していることは、抗生物質市場を加速させる主な要因の一つです。感染症は、細菌、ウイルス、真菌、寄生虫などの生物によって引き起こされる疾患です。一般的な風邪からCOVID-19まで、障害の大部分はこれらの外来疾患の存在によるものです。抗生物質は、尿路感染症、副鼻腔感染症、皮膚感染症、耳感染症など、さまざまな感染症の治療に利用されています。

CDC、およびNational Centre for Health Statisticsの情報源によると、米国における2019年の新規結核、サルモネラ、ライム病、髄膜炎菌感染症の数はそれぞれ8,916、58,371、34,945、371でした。

さらに、世界保健機関（WHO）の2022年10月の報告によると、2020年に結核が原因で死亡した人は世界で約150万人、結核で倒れた人は世界で約1,000万人となっています。WHOの同出典によれば、2020年の結核の推定新規患者のうち、110万人が小児であり、結核患者の86％が結核負荷の高い30カ国から報告されています。

従って、このような感染症の増加は、抗生物質市場の需要を世界的に増大させることになります。さらに、感染症の増加は、新規治療法を開発するための大手製薬会社による研究開発活動の活発化も意味し、2024～2030年の予測期間における抗生物質市場の成長に拍車をかけることになります。

当レポートでは、世界の抗生物質市場について調査し、市場の概要とともに、製品タイプ別、スペクトル別、薬剤原料別、投与経路別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 抗生物質市場レポートのイントロダクション

第2章 抗生物質市場のエグゼクティブサマリー

第3章 抗生物質市場の主な要因分析

• 抗生物質市場の促進要因
• 抗生物質市場の抑制要因と課題
• 抗生物質市場の機会

第4章 抗生物質市場におけるポーターのファイブフォース分析

第5章 抗生物質市場に対するCOVID-19の影響分析

第6章 抗生物質市場の概要

• 製品タイプ別
• スペクトル別
• 薬剤原料別
• 投与経路別
• 地域別

第7章 抗生物質市場の企業と製品プロファイル

• GlaxoSmithKline PLC.
• Johnson & Johnson Inc.
• Merck & Co. Inc.
• Pfizer Inc.
• Bayer Healthcare AG
• Novartis AG
• Sanofi SA
• Abbott Laboratories
• F. Hoffmann-La Roche AG
• Otsuka Pharmaceutical Co. Ltd
• Eli Lilly and Company
• Daiichi Sankyo
• Astellas Pharma
• Melinta Therapeutics Inc.
• Allergan PLC.
• Basilea Pharmaceutical Ltd
• Tetraphase Pharmaceuticals
• Spero Therapeutics
• Paratek Pharmaceuticals
• Nabriva Therapeutics

第8章 KOL の見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightについて

第11章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Antibiotics Market
• Table 3: Antibiotics Market in Global (2021-2030)
• Table 4: Antibiotics Market in Global by Product Type (2021-2030)
• Table 5: Antibiotics Market in Global by Spectrum (2021-2030)
• Table 6: Antibiotics Market in Global by Drug Origin (2021-2030)
• Table 7: Antibiotics Market in Global by Route of Administration (2021-2030)
• Table 8: Antibiotics Market in Global by Geography (2021-2030)
• Table 9: Antibiotics Market in North America (2021-2030)
• Table 10: Antibiotics Market in North America by Country (2021-2030)
• Table 11: Antibiotics Market in the US (2021-2030)
• Table 12: Antibiotics Market in Canada (2021-2030)
• Table 13: Antibiotics Market in Mexico (2021-2030)
• Table 14: Antibiotics Market in Europe (2021-2030)
• Table 15: Antibiotics Market in Europe by Country (2021-2030)
• Table 16: Antibiotics Market in France (2021-2030)
• Table 17: Antibiotics Market in Germany (2021-2030)
• Table 18: Antibiotics Market in the United Kingdom (2021-2030)
• Table 19: Antibiotics Market in Italy (2021-2030)
• Table 20: Antibiotics Market in Spain (2021-2030)
• Table 21: Antibiotics Market in Rest of Europe (2021-2030)
• Table 22: Antibiotics Market in APAC (2021-2030)
• Table 23: Antibiotics Market in APAC by Country (2021-2030)
• Table 24: Antibiotics Market in China (2021-2030)
• Table 25: Antibiotics Market in Japan (2021-2030)
• Table 26: Antibiotics Market in India (2021-2030)
• Table 27: Antibiotics Market in Australia (2021-2030)
• Table 28: Antibiotics Market in South Korea (2021-2030)
• Table 29: Antibiotics Market in Rest of APAC (2021-2030)
• Table 30: Antibiotics Market in Rest of World (2021-2030)
• Table 31: Antibiotics Market in RoW by Region (2021-2030)
• Table 32: Antibiotics Market in Middle East (2021-2030)
• Table 33: Antibiotics Market in Africa (2021-2030)
• Table 34: Antibiotics Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Antibiotics Market
• Figure 3: Antibiotics Market in Global (2021-2030)
• Figure 4: Antibiotics Market in Global by Product Type (2021-2030)
• Figure 5: Antibiotics Market in Global by Spectrum (2021-2030)
• Figure 6: Antibiotics Market in Global by Drug Origin (2021-2030)
• Figure 7: Antibiotics Market in Global by Route of Administration (2021-2030)
• Figure 8: Antibiotics Market in Global by Geography (2021-2030)
• Figure 9: Antibiotics Market in North America (2021-2030)
• Figure 10: Antibiotics Market in North America by Country (2021-2030)
• Figure 11: Antibiotics Market in the US (2021-2030)
• Figure 12: Antibiotics Market in Canada (2021-2030)
• Figure 13: Antibiotics Market in Mexico (2021-2030)
• Figure 14: Antibiotics Market in Europe (2021-2030)
• Figure 15: Antibiotics Market in Europe by Country (2021-2030)
• Figure 16: Antibiotics Market in France (2021-2030)
• Figure 17: Antibiotics Market in Germany (2021-2030)
• Figure 18: Antibiotics Market in the United Kingdom (2021-2030)
• Figure 19: Antibiotics Market in Italy (2021-2030)
• Figure 20: Antibiotics Market in Spain (2021-2030)
• Figure 21: Antibiotics Market in Rest of Europe (2021-2030)
• Figure 22: Antibiotics Market in APAC (2021-2030)
• Figure 23: Antibiotics Market in APAC by Country (2021-2030)
• Figure 24: Antibiotics Market in China (2021-2030)
• Figure 25: Antibiotics Market in Japan (2021-2030)
• Figure 26: Antibiotics Market in India (2021-2030)
• Figure 27: Antibiotics Market in Australia (2021-2030)
• Figure 28: Antibiotics Market in South Korea (2021-2030)
• Figure 29: Antibiotics Market in Rest of APAC (2021-2030)
• Figure 30: Antibiotics Market in Rest of World (2021-2030)
• Figure 31: Antibiotics Market in RoW by Region (2021-2030)
• Figure 32: Antibiotics Market in Middle East (2021-2030)
• Figure 33: Antibiotics Market in Africa (2021-2030)
• Figure 34: Antibiotics Market in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Marker Opportunities
• Figure 38: PORTER'S Five Force Analysis

Antibiotics Market By Product Type (Cephalosporin, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Aminoglycoside, Sulfonamide, And Others), By Spectrum (Broad-Spectrum Antibiotics And Narrow-Spectrum), By Drug Origin (Natural And Synthetic), By Route Of Administration (Oral, Intravenous And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to rising prevalence of infectious diseases and increased consumption of antibiotics in low and middle-income countries

The global antibiotics market was valued at USD 44.20 billion in 2023, growing at a CAGR of 4.91% during the forecast period from 2024 to 2030 to reach USD 58.90 billion by 2030. The antibiotics market is slated to witness prosperity owing to factors such as the rising prevalence of infectious diseases, increased consumption of antibiotics in low and middle-income countries, increased research and development to develop advanced therapies, and a growing geriatric population which is susceptible to the infectious disorder are further expected to result in the appreciable revenue growth in the antibiotics market during the forecast period (2024-2030).

Antibiotics Market Dynamics:

Among the noteworthy drivers of the antibiotics market, the increasing prevalence of infectious diseases that are required to be treated with antibiotics is one of the major factors responsible for accelerating the antibiotics market. Infectious diseases are disorders caused by organisms such as bacteria, viruses, fungi, or parasites. From a common cold to COVID-19, the majority of disorders are due to the presence of these foreign ailments. Antibiotics are utilized in treating different infectious disorders such as urinary tract infections, sinus infections, skin, and ear infections among others.

As per CDC, and National Centre for Health Statistics sources, the number of new tuberculosis, salmonella, Lyme disease, and meningococcal disease in the US were 8,916; 58,371; 34,945, and 371 in 2019 respectively.

Moreover, according to the October 2022 report of the World Health Organization (WHO), about 1.5 million people worldwide died because of tuberculosis in 2020, and approximately 10 million people fell ill with TB globally. As per the same source from WHO, of the estimated new cases of tuberculosis in 2020, 1.1 million were in children, and 86% of the TB cases were reported from the 30 high TB burden countries.

Thus, this increased number of infectious disorders will in turn increase the demand for the antibiotics market globally. Furthermore, the increase in the number of infectious disorders also means increased research and developmental activities by major pharmaceutical companies to develop novel therapies, thereby fueling the growth of the antibiotics market in the forecast period of 2024-2030.

According to Pew Charitable Trust, in December 2019, around 41 promising molecules were being investigated for the treatment of serious bacterial infections. Out of these 41 investigational drugs, 17 are in the third phase of the clinical trials or have filed NDA for approval and are expected to be commercialized during the forecast period. In the second half of 2019, four new antibiotic drugs received U.S. FDA approval.

Thus, all the above factors point toward positive market growth in the forecast period of 2024-2030.

The increased infectious disorders and increased R&D activities by pharmaceutical manufacturers also call for supportive governmental policies which will further act as fuel in the growth of the antibiotics market. For instance, BARDA in alliance with the government has extended its support to several companies to aid the development process of new therapies for infectious diseases. Furthermore, supportive government legislation such as the GAIN Act and REVAMP Act is anticipated to expedite the approval process globally.

COVID-19 impacted the global supply chain of pharmaceuticals, affecting the antibiotics market. However, many antibiotics were initially used to treat COVID-19 and are widely prescribed and studied as the COVID-19 remedy. For instance, in March 2020, Pfizer announced positive data for using its azithromycin (Zithromax) drug, along with hydroxychloroquine, in a coronavirus clinical trial performed in France. There was a huge demand for antibiotics during the COVID-19 pandemic.

Furthermore, climate change and urbanization, changing ecosystems, an increase in the geriatric population prone to infectious diseases, and an increasing number of public-private collaborations are other few of the factors that will drive the growth of the antibiotics market during the forecast period from 2024-2030.

However, antibiotic resistance features of the bacteria which are compelling pharmaceutical companies to shift their focus from antibiotics and concentrate on newer technologies and stringent regulatory approvals for antibiotics are a few of the market restraints which will impact the market growth during the forecast period from 2024-2030.

Antibiotics Market Segment Analysis:

Antibiotics Market By Product Type (Cephalosporin, Penicillin, Fluroquinilone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamide, and Others), By Spectrum (Broad-Spectrum Antibiotics and Narrow-Spectrum), By Drug Origin (Natural and Synthetic), By Route of Administration (Oral, Intravenous and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the product type segment of the antibiotics market, penicillin accounted for the largest market share in the base year 2022. This can be ascribed to the largest number of generic manufacturers in the space.

Penicillin is a narrow-range antibiotic that covers gram-positive bacteria and some gram-negative bacteria. Penicillin can be given as an injection as well as an oral tablet or liquid suspension.

Penicillin is one of the oldest antibiotics seen in the market, various new and advanced versions of it are now available in the market, such as Amoxicillin. It is a newer version of penicillin that covers more types of bacteria. Amoxicillin was created by modifying the original chemical structure of penicillin to make it more potent. It is considered a broad-range antibiotic that covers a wider variety of bacteria compared to penicillin.

Penicillin is used in the treatment of throat infections, meningitis, syphilis, and various other infections. Therefore, considering the broad range of diseases that are treated by penicillin and the advantages associated with using penicillin are expected to contribute to the dominant market share.

Asia Pacific is expected to dominate the overall Antibiotics Market:

Among all the regions, Asia-Pacific is expected to lead in revenue generation in the global antibiotics market. This can be ascribed to the increasing prevalence of bacterial infections in the region, increasing usage of antibiotics for various diseases, and the local presence of key market players among other factors in the region.

One of the prominent factors supporting the growth of the Asia-Pacific antibiotics market is the high prevalence rate of infectious diseases across the region. Asia-Pacific particularly South East Asia is a biodiversity hub. However rapid urbanization has led to disturbed ecosystems and a rise in the prevalence of infectious diseases.

According to WHO, Global Tuberculosis Report 2022, Southeast Asia accounted for 43%, and the Western Pacific for 18% of the global burden of TB in 2020.

Furthermore, a growing geriatric population in the Asia-Pacific region is also a factor contributing to the dominant market share.

As per UNFPA, the number of older people in the Asia-Pacific region is rising at an unprecedented rate by 2050, one in four people in Asia and the Pacific will be over 60 years old.

Apart from this, the presence of many regional players in Asia-Pacific for antibiotics manufacturers is also a key factor for the dominance in the market arena.

Therefore, the above-mentioned factors are expected to bolster the growth of the antibiotics market in the Asia-Pacific region during the forecast period.

Antibiotics Market Key Players:

Some of the key market players operating in the antibiotics market include GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., Bayer Healthcare AG, Novartis AG, Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche AG, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Daiichi Sankyo, Astellas Pharma, Melinta Therapeutics Inc., Allergan plc., Basilea Pharmaceutica Ltd, Tetraphase Pharmaceuticals, Spero Therapeutics, Paratek Pharmaceuticals, Inc., Nabriva Therapeutics plc. and others.

Recent Developmental Activities in the Antibiotics Market:

In October 2022, Sandoz, a Novartis division, acquired GSK's cephalosporin antibiotics business. It now has the rights to three well-known brands namely Zinnat, Zinacef, and Fortum in more than 100 markets, strengthening its position as the world's leading antibiotics company.

In August 2022, Japan-based Otsuka Pharmaceutical has been awarded a grant for up to USD 17.8 million to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid and Johnson & Johnson's for patients with drug-susceptible pulmonary tuberculosis (DS-TB).

Key Takeaways from the Antibiotics Market Report Study

• Market size analysis for current antibiotics market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the antibiotics market.
• Top key product developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global antibiotics market.
• Various opportunities were available for the other competitor in the antibiotics market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current antibiotics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for antibiotics market growth in the coming future?

Target Audience who can be benefited from this Antibiotics Market Report Study

• Antibiotics products providers
• Research organizations and consulting companies
• Antibiotics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Antibiotics
• Various distribution channels to know more about the antibiotics market and the latest product innovations in the antibiotics market.

Frequently Asked Questions for Antibiotics Market:

1. What are Antibiotics?

Antibiotics are medicines that fight bacterial infections in people and animals. They work by killing the bacteria or by making it hard for the bacteria to grow and multiply.

2. What is the market for global Antibiotics?

The global antibiotics market was valued at USD 44.20 billion in 2023, growing at a CAGR of 4.91% during the forecast period from 2024 to 2030 to reach USD 58.90 billion by 2030.

3. What are the drivers for the global Antibiotics market?

The antibiotics market is slated to witness prosperity owing to factors such as the rising prevalence of infectious diseases, increased consumption of antibiotics in low and middle-income countries, increased research and development to develop advanced therapies, and a growing geriatric population which is susceptible to the infectious disorder are further expected to result in the appreciable revenue growth in the antibiotics market during the forecast period (2024-2030).

4. Who are the key players operating in the global Antibiotics market?

Some of the key market players operating in the antibiotics market include GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., Bayer Healthcare AG, Novartis AG, Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche AG, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Daiichi Sankyo, Astellas Pharma, Melinta Therapeutics Inc., Allergan plc., Basilea Pharmaceutical Ltd, Tetraphase Pharmaceuticals, Spero Therapeutics, Paratek Pharmaceuticals, Inc., Nabriva Therapeutics plc. and others.

5. Which region has the highest share in the Antibiotics market?

Among all the regions, Asia-Pacific is expected to lead in revenue generation in the global antibiotics market. This can be ascribed to the increasing prevalence of bacterial infections in the region, increasing usage of antibiotics for various diseases, and the local presence of key market players among other factors in the region.

Table of Contents

1.Antibiotics Market Report Introduction

2. Antibiotics Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Antibiotics Market Key Factors Analysis

• 3.1. Antibiotics Market Drivers
  • 3.1.1. Rising prevalence of infectious disease
  • 3.1.2. Increased consumption of antibiotics in low and middle-income countries
  • 3.1.3. Increased research and development to develop advanced therapies
  • 3.1.4. The growing geriatric population who is susceptible to the infectious disorder
• 3.2. Antibiotics Market Restraints and Challenges
  • 3.2.1. Stringent Regulatory Approvals
  • 3.2.2. Antibiotic Resistance property of bacteria
• 3.3. Antibiotics Market Opportunities
  • 3.3.1. Increase in Governmental Initiatives and Funds

4. Antibiotics Market Porter's Five Forces Analysis

• 4.1. Bargaining Power of Suppliers
• 4.2. Bargaining Power of Consumers
• 4.3. Threat of New Entrants
• 4.4. Threat of Substitutes
• 4.5. Competitive Rivalry

5. COVID-19 Impact Analysis on Antibiotics Market

6. Antibiotics Market Layout

• 6.1. By Product Type
  • 6.1.1. Cephalosporin
  • 6.1.2. Penicillin
  • 6.1.3. Fluroquinilone
  • 6.1.4. Macrolides
  • 6.1.5. Carbapenem
  • 6.1.6. Aminoglycoside
  • 6.1.7. Sulfonamide
  • 6.1.8. Others
• 6.2. By Spectrum
  • 6.2.1. Broad-Spectrum Antibiotics
  • 6.2.2. Narrow-Spectrum
• 6.3. By Drug Origin
  • 6.3.1. Natural
  • 6.3.2. Synthetic
• 6.4. By Route of Administration
  • 6.4.1. Oral
  • 6.4.2. Intravenous
  • 6.4.3. Others
• 6.5. By Geography
  • 6.5.1. North America
    • 6.5.1.1. United States Antibiotics Market in USD million (2021-2030)
    • 6.5.1.2. Canada Antibiotics Market in USD million (2021-2030)
    • 6.5.1.3. Mexico Antibiotics Market in USD million (2021-2030)
  • 6.5.2. Europe
    • 6.5.2.1. France Antibiotics Market in USD million (2021-2030)
    • 6.5.2.2. Germany Antibiotics Market in USD million (2021-2030)
    • 6.5.2.3. United Kingdom Antibiotics Market in USD million (2021-2030)
    • 6.5.2.4. Italy Antibiotics Market in USD million (2021-2030)
    • 6.5.2.5. Spain Antibiotics Market in USD million (2021-2030)
    • 6.5.2.6. Rest of Europe Antibiotics Market in USD million (2021-2030)
  • 6.5.3. Asia-Pacific
    • 6.5.3.1. China Antibiotics Market in USD million (2021-2030)
    • 6.5.3.2. Japan Antibiotics Market in USD million (2021-2030)
    • 6.5.3.3. India Antibiotics Market in USD million (2021-2030)
    • 6.5.3.4. Australia Antibiotics Market in USD million (2021-2030)
    • 6.5.3.5. South Korea Antibiotics Market in USD million (2021-2030)
    • 6.5.3.6. Rest of the Asia Pacific Antibiotics Market in USD million (2021-2030)
  • 6.5.4. Rest of the World (RoW)
    • 6.5.4.1. Middle East Antibiotics Market in USD million (2021-2030)
    • 6.5.4.2. Africa Antibiotics Market in USD million (2021-2030)
    • 6.5.4.3. South America Antibiotics Market in USD million (2021-2030)

7. Antibiotics Market Company and Product Profiles

• 7.1. GlaxoSmithKline PLC.
  • 7.1.1. Company Overview
  • 7.1.2. Company Snapshot
  • 7.1.3. Financial Overview
  • 7.1.4. Product Listing
  • 7.1.5. Entropy
• 7.2. Johnson & Johnson Inc.
  • 7.2.1. Company Overview
  • 7.2.2. Company Snapshot
  • 7.2.3. Financial Overview
  • 7.2.4. Product Listing
  • 7.2.5. Entropy
• 7.3. Merck & Co. Inc.
  • 7.3.1. Company Overview
  • 7.3.2. Company Snapshot
  • 7.3.3. Financial Overview
  • 7.3.4. Product Listing
  • 7.3.5. Entropy
• 7.4. Pfizer Inc.
  • 7.4.1. Company Overview
  • 7.4.2. Company Snapshot
  • 7.4.3. Financial Overview
  • 7.4.4. Product Listing
  • 7.4.5. Entropy
• 7.5. Bayer Healthcare AG
  • 7.5.1. Company Overview
  • 7.5.2. Company Snapshot
  • 7.5.3. Financial Overview
  • 7.5.4. Product Listing
  • 7.5.5. Entropy
• 7.6. Novartis AG
  • 7.6.1. Company Overview
  • 7.6.2. Company Snapshot
  • 7.6.3. Financial Overview
  • 7.6.4. Product Listing
  • 7.6.5. Entropy
• 7.7. Sanofi SA
  • 7.7.1. Company Overview
  • 7.7.2. Company Snapshot
  • 7.7.3. Financial Overview
  • 7.7.4. Product Listing
  • 7.7.5. Entropy
• 7.8. Abbott Laboratories
  • 7.8.1. Company Overview
  • 7.8.2. Company Snapshot
  • 7.8.3. Financial Overview
  • 7.8.4. Product Listing
  • 7.8.5. Entropy
• 7.9. F. Hoffmann-La Roche AG
  • 7.9.1. Company Overview
  • 7.9.2. Company Snapshot
  • 7.9.3. Financial Overview
  • 7.9.4. Product Listing
  • 7.9.5. Entropy
• 7.10. Otsuka Pharmaceutical Co. Ltd
  • 7.10.1. Company Overview
  • 7.10.2. Company Snapshot
  • 7.10.3. Financial Overview
  • 7.10.4. Product Listing
  • 7.10.5. Entropy
• 7.11. Eli Lilly and Company
  • 7.11.1. Company Overview
  • 7.11.2. Company Snapshot
  • 7.11.3. Financial Overview
  • 7.11.4. Product Listing
  • 7.11.5. Entropy
• 7.12. Daiichi Sankyo
  • 7.12.1. Company Overview
  • 7.12.2. Company Snapshot
  • 7.12.3. Financial Overview
  • 7.12.4. Product Listing
  • 7.12.5. Entropy
• 7.13. Astellas Pharma
  • 7.13.1. Company Overview
  • 7.13.2. Company Snapshot
  • 7.13.3. Financial Overview
  • 7.13.4. Product Listing
  • 7.13.5. Entropy
• 7.14. Melinta Therapeutics Inc.
  • 7.14.1. Company Overview
  • 7.14.2. Company Snapshot
  • 7.14.3. Financial Overview
  • 7.14.4. Product Listing
  • 7.14.5. Entropy
• 7.15. Allergan PLC.
  • 7.15.1. Company Overview
  • 7.15.2. Company Snapshot
  • 7.15.3. Financial Overview
  • 7.15.4. Product Listing
  • 7.15.5. Entropy
• 7.16. Basilea Pharmaceutical Ltd
  • 7.16.1. Company Overview
  • 7.16.2. Company Snapshot
  • 7.16.3. Financial Overview
  • 7.16.4. Product Listing
  • 7.16.5. Entropy
• 7.17. Tetraphase Pharmaceuticals
  • 7.17.1. Company Overview
  • 7.17.2. Company Snapshot
  • 7.17.3. Financial Overview
  • 7.17.4. Product Listing
  • 7.17.5. Entropy
• 7.18. Spero Therapeutics
  • 7.18.1. Company Overview
  • 7.18.2. Company Snapshot
  • 7.18.3. Financial Overview
  • 7.18.4. Product Listing
  • 7.18.5. Entropy
• 7.19. Paratek Pharmaceuticals
  • 7.19.1. Company Overview
  • 7.19.2. Company Snapshot
  • 7.19.3. Financial Overview
  • 7.19.4. Product Listing
  • 7.19.5. Entropy
• 7.20. Nabriva Therapeutics
  • 7.20.1. Company Overview
  • 7.20.2. Company Snapshot
  • 7.20.3. Financial Overview
  • 7.20.4. Product Listing
  • 7.20.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us